Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

137 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Management of toxicities of immune checkpoint inhibitors.
Spain L, Diem S, Larkin J. Spain L, et al. Among authors: diem s. Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6. Cancer Treat Rev. 2016. PMID: 26874776 Review.
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
Richman J, Martin-Liberal J, Diem S, Larkin J. Richman J, et al. Among authors: diem s. Expert Opin Pharmacother. 2015 Jun;16(9):1285-97. doi: 10.1517/14656566.2015.1044971. Expert Opin Pharmacother. 2015. PMID: 26001180 Review.
Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J. Diem S, et al. Eur J Cancer. 2015 Dec;51(18):2785-91. doi: 10.1016/j.ejca.2015.09.007. Epub 2015 Nov 18. Eur J Cancer. 2015. PMID: 26597444
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Diem S, et al. Br J Cancer. 2016 Feb 2;114(3):256-61. doi: 10.1038/bjc.2015.467. Epub 2016 Jan 21. Br J Cancer. 2016. PMID: 26794281 Free PMC article.
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O. Bowyer S, et al. Among authors: diem s. Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28. Br J Cancer. 2016. PMID: 27124339 Free PMC article.
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L. Diem S, et al. J Immunother. 2016 Nov/Dec;39(9):379-382. doi: 10.1097/CJI.0000000000000143. J Immunother. 2016. PMID: 27662340
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J. Morganstein DL, et al. Among authors: diem s. Clin Endocrinol (Oxf). 2017 Apr;86(4):614-620. doi: 10.1111/cen.13297. Epub 2017 Jan 27. Clin Endocrinol (Oxf). 2017. PMID: 28028828
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O. Bowyer S, et al. Among authors: diem s. Br J Cancer. 2017 Apr 11;116(8):e15. doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21. Br J Cancer. 2017. PMID: 28324885 Free PMC article. No abstract available.
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L. Hasan Ali O, et al. Among authors: diem s. Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529903 Clinical Trial.
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L. Fässler M, et al. Among authors: diem s. J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2. J Immunother Cancer. 2019. PMID: 30786924 Free PMC article. Clinical Trial.
137 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback